Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501

K Prilliman, M Lindsey, Y Zuo, KW Jackson, Y Zhang… - Immunogenetics, 1997 - Springer
K Prilliman, M Lindsey, Y Zuo, KW Jackson, Y Zhang, W Hildebrand
Immunogenetics, 1997Springer
A peptide-based vaccine must be bound and presented by major histocompatibility complex
class I molecules to elicit a CD8+ T-cell response. Because class I HLA molecules are highly
polymorphic, it has yet to be established how well a vaccine peptide that stimulates one
individual's CD8+ cytotoxic T lymphocytes will be presented by a second individual's
different class I molecules. Therefore, to facilitate precise comparisons of class I peptide
binding overlaps, we uniquely combined hollow-fiber bioreactors and mass spectrometry to …
Abstract
 A peptide-based vaccine must be bound and presented by major histocompatibility complex class I molecules to elicit a CD8+ T-cell response. Because class I HLA molecules are highly polymorphic, it has yet to be established how well a vaccine peptide that stimulates one individual’s CD8+ cytotoxic T lymphocytes will be presented by a second individual’s different class I molecules. Therefore, to facilitate precise comparisons of class I peptide binding overlaps, we uniquely combined hollow-fiber bioreactors and mass spectrometry to assign precise peptide binding signatures to individual class I HLA molecules. In applying this strategy to HLA-B*1501, we isolated milligram quantities of B*1501-bound peptides and mapped them using mass spectrometry. Repeated analyses consistently assign the same peptide binding signature to B*1501; the degree of peptide binding overlap between any two class I molecules can thus be determined through comparison of their peptide signatures.
Springer